KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles: 2011-2024

Historic Intangibles for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $521.9 million.

  • Supernus Pharmaceuticals' Intangibles rose 15.43% to $623.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $623.5 million, marking a year-over-year increase of 15.43%. This contributed to the annual value of $521.9 million for FY2024, which is 13.00% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Intangibles of $521.9 million as of FY2024, which was down 13.00% from $599.9 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Intangibles registered a high of $784.7 million during FY2021, and its lowest value of $364.3 million during FY2020.
  • Its 3-year average for Intangibles is $608.1 million, with a median of $599.9 million in 2023.
  • In the last 5 years, Supernus Pharmaceuticals' Intangibles surged by 1,366.76% in 2020 and then declined by 14.60% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Intangibles stood at $364.3 million in 2020, then soared by 115.37% to $784.7 million in 2021, then fell by 10.48% to $702.5 million in 2022, then dropped by 14.60% to $599.9 million in 2023, then fell by 13.00% to $521.9 million in 2024.